Literature DB >> 20644949

Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter.

Karl Strecker1, Florian Wegner, Swen Hesse, Georg-Alexander Becker, Marianne Patt, Philipp M Meyer, Donald Lobsien, Johannes Schwarz, Osama Sabri.   

Abstract

Recent imaging and neuropathological studies indicate reduced serotonin transporter (SERT) in advanced Parkinson's disease (PD). However, data on SERT in early PD patients are sparse. Following the hypothesis that the serotonergic system is damaged early in PD, the aim of our study was to investigate SERT availability by means of PET imaging. Since the loss of dopaminergic neurons is the pathologic hallmark of PD and SERT might be associated with psychiatric co-morbidity, we further sought to correlate SERT availability with the availability of dopamine transporter (DAT) and depressive or motor symptoms in early PD. We prospectively recruited nine early PD patients (4 female, 5 male; 42-76 years) and nine age matched healthy volunteers (5 female, 4 male; 42-72 years). Diagnosis of PD was confirmed by the UK brain bank criteria and DAT imaging. SERT availability was measured by means of [11C]DASB PET. For neuropsychiatric assessment done on the day of PET we applied UPDRS parts I, II and III, Beck's Depression Inventory, Hamilton Rating Scale for Depression, Mini-Mental State Examination and Demtect. SERT was not reduced in any of 14 investigated regions of interest in the nine PD patients compared to healthy controls (p>0.13). SERT was negatively associated with DAT in the striatum (r=-0.69; p=0.04) but not within the midbrain. There was no correlation of SERT availability with depressive symptoms. No alteration of SERT binding in our patients suggests that the serotonergic system is remarkably preserved in early PD. Correlation with DAT might point to a compensatory regulation of the serotonergic system in early stages of PD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20644949     DOI: 10.1007/s00415-010-5666-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  33 in total

Review 1.  The "serotonin hypothesis" for depression in Parkinson's disease.

Authors:  R Mayeux
Journal:  Adv Neurol       Date:  1990

Review 2.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

3.  Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain.

Authors:  Masanori Ichise; Jeih-San Liow; Jian-Qiang Lu; Akihiro Takano; Kendra Model; Hiroshi Toyama; Tetsuya Suhara; Kazutoshi Suzuki; Robert B Innis; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2003-09       Impact factor: 6.200

4.  Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson's disease within one-year follow-up.

Authors:  Swen Hesse; Karl Strecker; Dirk Winkler; Julia Luthardt; Christoph Scherfler; Annegret Reupert; Christian Oehlwein; Henryk Barthel; Jens-Peter Schneider; Florian Wegner; Philipp Meyer; Jürgen Meixensberger; Osama Sabri; Johannes Schwarz
Journal:  J Neurol       Date:  2008-05-02       Impact factor: 4.849

5.  The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease.

Authors:  A F Leentjens; F R Verhey; G J Luijckx; J Troost
Journal:  Mov Disord       Date:  2000-11       Impact factor: 10.338

6.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

7.  Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease.

Authors:  G M Halliday; P C Blumbergs; R G Cotton; W W Blessing; L B Geffen
Journal:  Brain Res       Date:  1990-02-26       Impact factor: 3.252

8.  Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study.

Authors:  Sean S O'Sullivan; David R Williams; David A Gallagher; Luke A Massey; Laura Silveira-Moriyama; Andrew J Lees
Journal:  Mov Disord       Date:  2008-01       Impact factor: 10.338

Review 9.  Non-motor symptoms in Parkinson's disease.

Authors:  W Poewe
Journal:  Eur J Neurol       Date:  2008-04       Impact factor: 6.089

10.  [Neurobiologic and pharmacologic studies on the pathogenesis of Parkinson disease].

Authors:  T Brücke; P Riederer
Journal:  Wien Med Wochenschr       Date:  1986-08-31
View more
  17 in total

Review 1.  Depression in Parkinson's disease.

Authors:  J Schwarz; P Odin; C Buhmann; I Csoti; W Jost; U Wüllner; A Storch
Journal:  J Neurol       Date:  2011-05       Impact factor: 4.849

Review 2.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

3.  Is serotonin pathology a good biomarker in vivo for early Parkinson's disease?

Authors:  Celia Painous; Andres Perissinotti; Maria J Martí
Journal:  Ann Transl Med       Date:  2019-12

Review 4.  Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.

Authors:  Kathryn Lanza; Christopher Bishop
Journal:  J Neural Transm (Vienna)       Date:  2018-01-05       Impact factor: 3.575

5.  Cerebral serotonin transporter measurements with [11C]DASB: A review on acquisition and preprocessing across 21 PET centres.

Authors:  Martin Nørgaard; Melanie Ganz; Claus Svarer; Ling Feng; Masanori Ichise; Rupert Lanzenberger; Mark Lubberink; Ramin V Parsey; Marios Politis; Eugenii A Rabiner; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; Peter S Talbot; Federico Turkheimer; Stephen C Strother; Gitte M Knudsen
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-13       Impact factor: 6.200

6.  A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier.

Authors:  Daryl J Wile; Katie Dinelle; Nasim Vafai; Jessamyn McKenzie; Joseph K Tsui; Paul Schaffer; Yu-Shin Ding; Matthew Farrer; Vesna Sossi; A Jon Stoessl
Journal:  Mov Disord       Date:  2015-12-21       Impact factor: 10.338

Review 7.  [Nuclear medicine imaging in patients with Parkinson's syndrome: an update].

Authors:  J Schwarz
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

8.  Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson's disease without dementia.

Authors:  Yoon-Sang Oh; Jean Hee Kim; Sang-Won Yoo; Eo-Jin Hwang; Chul Hyoung Lyoo; Kwang-Soo Lee; Joong-Seok Kim
Journal:  Neurol Sci       Date:  2020-10-31       Impact factor: 3.307

Review 9.  The serotonergic system in motor and non-motor manifestations of Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox
Journal:  Exp Brain Res       Date:  2013-06-28       Impact factor: 1.972

10.  The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice.

Authors:  Karl Strecker; Michael Adamaszek; Sven Ohm; Florian Wegner; Jürgen Beck; Johannes Schwarz
Journal:  J Neural Transm (Vienna)       Date:  2012-05-10       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.